However, there is a limitation in developing small-molecule inhibitors to reduce tumorigenesis of ESCC because PTK7 is catalytically inactive, and the molecular mechanism of PTK7 has not yet been elucidated in ESCC. This evidence concerns the gene PTK7 and esophageal squamous cell carcinoma.